Posted on 12/1/20
Allena Pharmaceuticals Announces $10M Bought Deal Offering
NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics . . .
Posted on 12/1/20
BeiGene Launches Proposed Public Offering
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the commencement . . .
Posted on 12/1/20
CANbridge Pharmaceuticals Closes $43 Million Series E Financing
CANbridge Pharmaceuticals Inc., a company developing and commercializing innovative drugs to treat rare diseases and targeted cancers, announced that it has completed a US$43 million Series . . .
Posted on 12/1/20
Boston Scientific Divests BTG Specialty Pharmaceuticals Business for $800M
Boston Scientific (NYSE:BSX) entered into a definitive agreement to sell the its BTG Specialty Pharmaceuticals business to Stark International Lux and SERB SAS, affiliates of SERB, . . .
Posted on 12/1/20
Why Novavax Could Be a Bigger COVID Vaccine Winner Than Pfizer and Moderna
Some Americans could receive COVID-19 vaccinations before the end of 2020. Two coronavirus vaccines are in a prime position to win U.S. emergency use authorization (EUA) . . .
Posted on 12/1/20
Moderna's Coronavirus Vaccine Candidate 100% Effective at Preventing Severe COVID-19
On Monday morning, Moderna (NASDAQ:MRNA) released a highly encouraging primary efficacy analysis for its coronavirus vaccine candidate, mRNA-1273. The company also promised to submit a request . . .
Posted on 12/1/20
Moderna's Coronavirus Vaccine to Be Reviewed by FDA Advisory Committee on Dec. 17
Moderna (NASDAQ:MRNA) reported complete data for its coronavirus vaccine candidate, mRNA-1273, today. It also submitted its application for emergency use authorization to the Food and Drug . . .
Posted on 12/1/20
Cogent Biosciences Announces $60M Public Offering of Shares of Common Stock
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public . . .
Posted on 12/1/20
Intellia Therapeutics Proposes Public Offering of Common Stock
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both . . .
Posted on 11/30/20
Charlesbank Forms Bridges Consumer Healthcare,Acquires ThermaCare from GSK Consumer Healthcare
Funds affiliated with Charlesbank Capital Partners have announced the formation of Bridges Consumer Healthcare in partnership with industry executives Robert Long and Blair Ramey.
Posted on 11/30/20
Kinaset Therapeutics Launches with a $40M Series A Financing
Kinaset Therapeutics, Inc., a newly-founded biopharmaceutical company, today announced a $40 million Series A financing with a blue-chip investor syndicate of 5AM Ventures, Atlas Venture, and . . .
Posted on 11/30/20
Markel: The Berkshire Hathaway Of Insurance Is A Buy
SummaryMarkel has a differentiated model of investing its retained cash flows to buy other companies, similar to how Berkshire Hathaway operates.Its insurance business is profitable despite . . .
Posted on 11/30/20
Why Moderna Is Less Risky Than You Think
Biotech investing is not for the weak-hearted. While the clinical and regulatory success of a drug can mean huge gains, any failure in the development and . . .
Posted on 11/30/20
Craft Beer Is Being Drained by COVID-19
The craft beer industry is being crushed by the coronavirus pandemic. Already ailing from changing consumer preferences, small breweries are at a make-or-break point that could . . .
Posted on 11/30/20
3 Key Advantages Moderna Holds Over Pfizer and AstraZeneca
Pfizer (NYSE:PFE) appears to be likely to be the first drugmaker, along with its partner BioNTech (NASDAQ:BNTX), to win U.S. emergency use authorization (EUA) for a . . .
Posted on 11/29/20
Biogen and Sage Therapeutics Announce Global Collaboration
CAMBRIDGE, Mass., Nov. 27, 2020 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration . . .
Posted on 11/27/20
SoClean Ranked 134 On Deloitte's 2020 Technology Fast 500 for North America
SoClean Inc., the smart health technology company, has been included on Deloitte's 2020 Technology Fast 500 list. Created to recognize the passion and dedication it takes . . .
Posted on 11/25/20
2 Ways Warren Buffett Made History in Q3
When Berkshire Hathaway (NYSE:BRK-A)(NYSE:BRK-B) CEO Warren Buffett speaks, Wall Street and investors intently listen. That's because Buffett has a track record few other money managers can . . .
Posted on 11/25/20
Will Moderna's Coronavirus Vaccine Really Change the Game?
Key Points In an interim analysis of Moderna’s phase 3 trial, all 11 cases of severe COVID-19 occurred in the placebo group.Moderna will soon complete a . . .
Posted on 11/25/20
Moderna Set to Sell 160 Million Coronavirus Vaccine Doses to EU
Score another pre-approval sale for coronavirus vaccine-maker Moderna (NASDAQ:MRNA). European Commission President Ursula von der Leyen has announced that the EC will ink a deal with . . .
Posted on 11/25/20
Stoke Therapeutics Closes Public Offering
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein . . .
Posted on 11/25/20
AVROBIO Closes Underwritten Public Offering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO, Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company, today announced the closing of its previously announced underwritten public offering of 5,000,000 shares . . .
Posted on 11/24/20
Elevian Closes $15 Million Equity Financing
Elevian, an emerging biotech company developing medicines that restore youthful regenerative capacity with the potential to treat and prevent multiple age-related diseases, today announced the closing . . .
Posted on 11/23/20
Catamaran Bio Launches with $42 Million Financing
Catamaran Bio, Inc., a biotechnology company developing allogeneic CAR-NK cell therapies to treat cancer, today announced that the company has launched with $42 million in financing.
Posted on 11/23/20
Here's Why Moderna's Coronavirus Vaccine Could Outsell Pfizer's
If you could get a coronavirus inoculation this afternoon, you probably wouldn't care if the clinician told you that the shot might feel a bit chilly. . . .
Boston
